RESONATE研究最终分析:伊布替尼治疗复发/难治CLL/SLL长达六年随访
RESONATE III期研究最终分析显示,中位随访65.3个月,伊布替尼组中位PFS显著长于奥法木单抗组(44.1 vs 8.1个月,HR 0.148,P<.001),高危基因组亚组获益一致,安全性长期可控。
要点
- 伊布替尼较奥法木单抗显著延长复发/难治CLL/SLL的中位PFS(44.1 vs 8.1个月,HR 0.148)。
- 高危基因组(del(17p)/TP53突变/del(11q)/IGHV未突变)患者PFS获益一致(44.1 vs 8.0个月,HR 0.110)。
- 长期安全性可控,因不良事件停药仅16%。
核心结论
- RESONATE最终分析证实伊布替尼在复发/难治CLL/SLL中具有持久且稳健的疗效,无论高危临床或基因组特征均获益,未发现预期外不良事件。
研究设计与样本
- III期RESONATE研究最终分析,比较单药伊布替尼与奥法木单抗治疗复发/难治CLL/SLL,伊布替尼组中位随访65.3个月(范围0.3-71.6)。
主要发现
- 伊布替尼组中位PFS显著长于奥法木单抗组(44.1 vs 8.1个月;HR 0.148;95%CI 0.113-0.196;P<.001)。
- 高危基因组患者(占82%)中位PFS为44.1 vs 8.0个月(HR 0.110;95%CI 0.080-0.152)。
- 伊布替尼总缓解率91%,完全缓解/骨髓恢复不完全的完全缓解率11%。
- 交叉校正后总生存伊布替尼优于奥法木单抗(HR 0.639;95%CI 0.418-0.975)。
关键数值与推荐
- 伊布替尼治疗长达71个月(中位41个月),所有级别(≥3级)高血压发生率为21%(9%),房颤为12%(6%)。
- 仅16%患者因不良事件停用伊布替尼。
临床怎么用
- 复发/难治CLL/SLL患者可优先考虑伊布替尼单药治疗,高危基因组特征者同样获益。
- 长期用药需监测高血压和房颤等不良事件,但多数患者可耐受并持续治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ibrutinib, a once-daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The phase 3 RESONATE study showed improved efficacy of single-agent ibrutinib over ofatumumab in patients with relapsed/refractory CLL/SLL, including those with high-risk features. Here we report the final analysis from RESONATE with median follow-up on study of 65.3 months (range, 0.3-71.6) in the ibrutinib arm. Median progression-free survival (PFS) remained significantly longer for patients randomized to ibrutinib vs ofatumumab (44.1 vs 8.1 months; hazard ratio [HR]: 0.148; 95% confidence interval [CI]: 0.113-0.196; P˂.001). The PFS benefit with ibrutinib vs ofatumumab was preserved in the genomic high-risk population with del(17p), TP53 mutation, del(11q), and/or unmutated IGHV status (median PFS 44.1 vs 8.0 months; HR: 0.110; 95% CI: 0.080-0.152), which represented 82% of patients. Overall response rate with ibrutinib was 91% (complete response/complete response with incomplete bone marrow recovery, 11%). Overall survival, censored for crossover, was better with ibrutinib than ofatumumab (HR: 0.639; 95% CI: 0.418-0.975). With up to 71 months (median 41 months) of ibrutinib therapy, the safety profile remained consistent with prior reports; cumulatively, all-grade (grade ≥3) hypertension and atrial fibrillation occurred in 21% (9%) and 12% (6%) of patients, respectively. Only 16% discontinued ibrutinib because of adverse events (AEs). These long-term results confirm the robust efficacy of ibrutinib in relapsed/refractory CLL/SLL irrespective of high-risk clinical or genomic features, with no unexpected AEs. This trial is registered at www.clinicaltrials.gov (NCT01578707).
引用
- Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019. PMID: 31512258. doi:10.1002/ajh.25638
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。